The practicality of nanoceria-PAN-based 68Ge/68Ga generator toward preparation of 68Ga-labeled cyclic RGD dimer as a potential PET radiotracer for tumor imaging

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 1, 2013, Pages 77-83

  Chakraborty, Sudipta ^a   Chakravarty, Rubel ^a   Sarma, Haladhar D ^a   Dash, Ashutosh ^a   Pillai, M R A ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

68Ga; Integrin v 3; Nanoceria polyacrylonitrile; PET radiotracer; RGD peptide

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; GALLIUM 1 4 7 10 TETRAAZACYCLODODECANE 1 4 7 10 TETRAACETIC ACID ARGINYLGLYCYLASPARTIC ACID GA 68; GALLIUM 68; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG STABILITY; DRUG TUMOR LEVEL; DRUG URINE LEVEL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; METASTASIS; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ROOM TEMPERATURE; TUMOR LOCALIZATION; URINARY EXCRETION;

ANIMALS; CERIUM; FEMALE; GALLIUM RADIOISOTOPES; GERMANIUM; MICE; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE GENERATORS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 84872199019     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1252     Document Type: Article

References (44)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15
3. Mousa SA. Mechanisms of angiogenesis in vascular disorders: Potential therapeutic targets. Drugs Future 1998;23:51
4. Carmeliet P. Mechanism of angiogenesis and arteriogenesis. Nat Med 2000;6:389
5. Eliceiri BP, Cheresh DA. The role of 'alpha v' integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103:1227
6. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008:49(Suppl 2):113S.
7. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin avb3 targeted radiotracers for tumor imaging. Mol Pharm 2006;3:472
8. Haubner R. avb3-integrin imaging: A new approach to characterize angiogenesis? Eur J Nucl Med Mol Imaging 2006;33:S54
9. Beer AJ, Schwaiger M. Imaging of integrin avb3 expression. Cancer Metastasis Rev 2008;27:631
10. Weber WA, Haubner R, Vabuliene E, et al. Tumor angiogenesis targeting using imaging agents. Q J Nucl Med 2001 45:179
11. Liu S, Robinson SP, Edwards DS. Integrin avb3 directed radiopharmaceuticals for tumor imaging. Drugs Future 2003;28:511
12. Kumar CC. Integrin avb3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003;4:123
13. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin avb3 for angiogenesis. Science 1994;264:569
14. Jin H, Varner J. Integrins: Roles in cancer development and as treatment targets. Br J Cancer 2004;90:561
15. Chen X, Park R, Shahinian AH, et al. 18F-labeled RGD peptide: Initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004;31:179
16. Li ZB, Chen K, Chen X. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin avb3 expression. Eur J Nucl Med Mol Imaging 2008;35:1100
17. Wu Y, Zhang X, Xiong Z, et al. MicroPET imaging of glioma integrin avb3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005;46:1707
18. Wu Z, Li ZB, Chen K, et al. MicroPET of tumor integrin avb3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med 2007;48:1536
19. Zhang X, Xiong Z, Wu Y, et al. Quantitative PET imaging of tumor integrin avb3 expression with 18F-FRGD2. J Nucl Med 2006;47:113
20. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated avb3 integrin in cancer patients by positron emission tomography and [18F] Galacto-RGD. PLoS Med 2005;2:e70
21. Beer AJ, Grosu AL, Carlsen J, et al. [18F]galacto-RGD positron emission tomography for imaging of avb3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6610
22. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008 49:879
23. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin avb3 expression in man. Clin Cancer Res 2006;12: 3942
24. Al-Nahhas A, Win Z, Szyszko T, et al. What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging 2007;34:1897
25. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med 2005:46(Suppl 1): 172S.
26. Zhernosekov KP, Filosofov DV, Baum RP, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48:1741
27. Chakravarty R, Sukhla R, Ram R, et al. Nanoceria-PAN composite-based advanced sorbent material: A major step forward in the field of clinical-Grade 68Ge/68Ga generator. Appl Materials Interfaces 2010;7:2069
28. Rosch F, Riss PJ. The renaissance of the 68Ge/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry. Curr Top Med Chem 2010;10: 1633
29. Asti M, De Pietri G, Fraternali A, et al. Validation of 68Ge/68Ga generator processing by chemical purification for routine clinical application of 68Ga-DOTATOC. Nucl Med Biol 2008;35:721
30. Gebhardt P, Opfermann TH, Saluz HP. Computer controlled 68Ga milking and concentration system. Appl Radiat Isot 2010;68:1057
31. Aardaneh K, Van Der Walt TN. Ga2O for target, solvent extraction for radiochemical separation and SnO2 for the preparation of a 68Ge/68Ga generator. J Radioanal Nucl Chem 2006;268:25
32. Liu S. Radiolabeled cyclic RGD peptides as integrin avb3 targeted radiotracers: Maximizing binding affinity via bivalency. Bioconj Chem 2009;20:2199
33. Chen X, Liu S, Hou Y, et al. MicroPET imaging of breast cancer av-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 2004;6:350
34. Janssen M, Oyen WJG, Dijkgraaf I, et al. Tumor targeting with radiolabeled avb3 integrin binding peptides in a nude mice model. Cancer Res 2002;62:6146
35. Janssen M, Oyen WJG, Massuger LFAG, et al. Comparison of a monomeric and dimeric radiolabeled RGDpeptide for tumor targeting. Cancer Biother Radiopharm 2002;17:641
36. Dijkgraaf I, Kruijtzer JAW, Liu S, et al. Improved targeting of the avb3 integrin by multimerization of RGD peptides. Eur J Nucl Med Mol Imaging 2007;34:267
37. Liu S, Hsieh WY, Jiang Y, et al. Evaluation of a 99mTc-labeled cyclic RGD tetramer for non-invasive imaging integrin avb3-positive breast cancer. Bioconj Chem 2007;18:438
38. Wang JJ, Kim YS, He ZJ, Liu S. 99mTc-labeling of HYNICconjugated cyclic RGDfK dimer and tetramer using EDDA as coligand. Bioconj Chem 2008;19:634
39. Shi J, Wang L, Kim YS, et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic Arginine-Glycine-Aspartic (RGD) dimers with triglycine linkers. J Med Chem 2008;51:7980
40. Chakraborty S, Shi J, Kim YS, et al. Evaluation of 111Inlabeled cyclic RGD peptides: Tetrameric not tetravalent. Bioconj Chem 2010;21:969
41. Dijkgraaf I, Yim CB, Franssen GM, et al. PET imaging of avb3 integrin expression in tumours with 68Ga-labelled mono-, diand tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 2010;37:1615
42. Shi J, Zhou Y, Chakraborty S, et al. Evaluation of 111Inlabeled cyclic RGD peptides: Effects of peptide and linker multiplicity on their tumor uptake, excretion kinetics and metabolic stability. Theranostics 2011;1:322
43. Awasthi V, Meinken G, Springer K, et al. Biodistribution of radioiodinated adenovirus fiber protein knob domain after intravenous injection in mice. J Virol 2004;78:6431
44. Panagi Z, Beletsi A, Evangelatos G, et al. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 2001;221:143